Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. (NYSE: WPI) was a Parsippany, New Jersey–based pharmaceutical company founded in 1984 (legacy roots in Libertyville, Illinois). It reported 2011 net revenue of roughly $4.6 billion with about 6,700 employees and a market capitalization near $7.6 billion at that time (company fact sheet). It was a public operating company, not an NPE.

Operations. Watson was an integrated specialty and generic pharmaceutical manufacturer: global generics (it described itself as the third-largest US generics company in 2011, with 750+ products marketed in more than 60 countries), branded products concentrated in urology and women's health (e.g., Rapaflo, Gelnique, Crinone, Generess Fe, Androderm), the Anda generic-drug distribution business, the Medis third-party out-licensing business, and a biosimilars pipeline. Following its October 2012 acquisition of the Actavis Group (€4.25 billion), Watson renamed itself Actavis, Inc. in January 2013 and later became Actavis plc/Allergan plc. As part of Allergan's 2016 sale of its generics business to Teva Pharmaceutical Industries, the Watson Laboratories, Inc. ANDA-holding subsidiary went to Teva; the former Watson Pharmaceuticals legal entity became Allergan Finance, LLC (a wholly owned Allergan/AbbVie subsidiary). The "Watson" name today persists mainly as an entity name in legacy litigation and FDA filings rather than an operating brand.

Litigation posture. In the tracked data, Watson Pharmaceuticals appears once, as a defendant (0 plaintiff cases), consistent with a generic manufacturer defending patent suits rather than asserting patents. The single case, Merck Sharp & Dohme Corp. v. Watson Laboratories, Inc. et al., was filed 2019-02-13 in the U.S. District Court for the District of Delaware.

Case context. That suit is a Hatch-Waxman ANDA action in which Merck alleged infringement of two Orange Book patents ('708 and '921) covering sitagliptin phosphate (Januvia/Janumet) against Watson and Teva entities. It was consolidated into MDL No. 2902 (In re Sitagliptin Phosphate ('708 & '921) Patent Litigation), also before Judge Richard G. Andrews in Delaware, alongside suits against Mylan, Sandoz, Lupin, Sun, and others; the case closed in November 2020. Delaware, not the Eastern District of Texas, is the typical venue for such pharmaceutical filings. Note the caption variance: dockets list the defendants as Watson Laboratories, Inc. and Teva entities, while MDL/PTAB filings reference "Watson Pharmaceuticals, Inc." in the same case number.